+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alpha 1 Antitrypsin Deficiency Treatment Market - Global Forecast 2026-2032- Product Image
Alpha 1 Antitrypsin Deficiency Treatment Market - Global Forecast 2026-2032- Product Image
New

Alpha 1 Antitrypsin Deficiency Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 189 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5887662
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The alpha-1 antitrypsin deficiency treatment market is evolving rapidly, shaped by innovations in gene and protein therapies, delivery models, and regulatory frameworks. Organizations anticipate significant change in therapeutic strategies, operational requirements, and stakeholder expectations.

Market Snapshot: Alpha-1 Antitrypsin Deficiency Treatment Market

The Alpha 1 Antitrypsin Deficiency Treatment Market grew from USD 3.53 billion in 2025 to USD 3.83 billion in 2026. It is projected to continue expanding at a CAGR of 9.78%, reaching USD 6.79 billion by 2032.

Scope & Segmentation

This report offers a comprehensive analysis across therapeutic modalities, distribution strategies, and geographic landscapes. The study segments the market along therapy innovation, patient demographics, and supply chain considerations to provide actionable insights.

  • Therapy Classes: Augmentation therapy, adeno-associated virus gene therapy, lentiviral vector approaches, and plasma infusion for acute scenarios.
  • Distribution Pathways: Hospital pharmacies for infusion and monitoring, online platforms for remote fulfillment, and retail pharmacy for broad access and dispensing support.
  • Delivery Modes: Inhalation-based systems, intravenous regimens, and protocols enabling home administration and outpatient care options.
  • Patient Demographics: Adults as the primary treated group, tailored strategies for geriatrics focused on comorbidity and safety, pediatric programs addressing age-appropriate dosing and long-term monitoring needs.
  • Geographies: Regional practices across the Americas, Europe, Middle East & Africa, and Asia-Pacific influencing clinical adoption, regulatory pathways, and commercial planning.
  • Technology Platforms: Vector biology, protein engineering, advanced plasma collection and formulation sciences, and telehealth-enabled monitoring.

Key Takeaways

  • Therapeutic options are transitioning from traditional plasma-derived augmentation to gene-based and molecular therapies, creating a pluralistic, multi-technology landscape.
  • Innovations in delivery modes and decentralized monitoring are driving the shift towards home-based management, reducing pressure on institutional care settings.
  • Supply chain resilience, manufacturing scalability, and real-world evidence are central priorities as manufacturers balance ambition with operational practicality.
  • Regional heterogeneity in clinical adoption, payer expectations, and logistics requires tailored, adaptive strategies for market entry and reimbursement negotiations.
  • Partnerships, technology alliances, and strategic acquisitions are redefining competitive positioning, supply reliability, and capacity to meet evolving demands.
  • Patient-centric care models and support services are gaining importance as treatment paradigms diversify.

Tariff Impact on Market Dynamics

Recent United States tariff realignments have affected supply chain strategies, increasing costs and altering sourcing decisions for complex therapies. Manufacturers face mounting input expenses, logistical uncertainties, and extended procurement timelines due to adjusted duties on raw materials and specialized components. Many firms are adopting mitigation strategies, including local supplier development and inventory optimization, to ensure continuity and cost competitiveness. Compliance functions now play an increasingly integral role in program planning as companies align manufacturing operations with trade incentives and seek to safeguard against further market shocks.

Methodology & Data Sources

The analysis integrates systematic reviews of peer-reviewed literature, clinical trial registries, regulatory filings, operational assessments, and expert interviews. Qualitative data from structured discussions with clinicians, supply chain leaders, and commercialization experts complement secondary research to deliver robust, actionable insights. Findings are triangulated and validated for consistency, emphasizing market-shaping trends over short-term fluctuations.

Why This Report Matters

  • Enables senior leaders to align pipeline priorities, resource allocation, and risk management with the realities of evolving therapeutic, regulatory, and supply landscapes.
  • Delivers segmentation-driven perspectives to support tailored go-to-market and patient access strategies across global regions.
  • Equips stakeholders with evidence-based recommendations to accelerate innovation adoption while managing uncertainty in costs, supply, and compliance.

Conclusion

Stakeholders attuned to operational rigor and adaptable strategy will be best positioned to convert therapeutic innovation into sustainable clinical and commercial outcomes. Successful programs will combine innovation with practical execution to expand patient access and optimize long-term value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Therapy Class
8.1. Augmentation Therapy
8.2. Gene Therapy
8.2.1. AAV Vector
8.2.2. Lentiviral Vector
8.3. Plasma Infusion
9. Alpha 1 Antitrypsin Deficiency Treatment Market, by Delivery Mode
9.1. Inhalation
9.2. Intravenous
10. Alpha 1 Antitrypsin Deficiency Treatment Market, by Patient Age Group
10.1. Adults
10.2. Geriatrics
10.3. Pediatrics
11. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Alpha 1 Antitrypsin Deficiency Treatment Market, by End User
12.1. Homecare
12.2. Hospitals
12.3. Specialty Clinics
13. Alpha 1 Antitrypsin Deficiency Treatment Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Alpha 1 Antitrypsin Deficiency Treatment Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Alpha 1 Antitrypsin Deficiency Treatment Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Alpha 1 Antitrypsin Deficiency Treatment Market
17. China Alpha 1 Antitrypsin Deficiency Treatment Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AstraZeneca PLC
18.6. Baxter International Inc.
18.7. Bayer AG
18.8. Biogen Inc.
18.9. Biotest AG
18.10. Boehringer Ingelheim International GmbH
18.11. CSL Behring GmbH
18.12. GlaxoSmithKline plc
18.13. Grifols S.A.
18.14. Kamada Pharmaceuticals
18.15. Takeda Pharmaceutical Company Limited
18.16. Vertex Pharmaceuticals
List of Figures
FIGURE 1. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 58. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 59. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 62. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 63. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 76. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 87. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 88. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 89. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 90. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 94. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 101. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 102. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 103. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 104. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 105. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 116. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 117. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 118. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 119. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 123. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 124. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 125. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 126. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 137. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 138. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 139. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 140. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 144. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 145. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 146. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 147. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 151. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 152. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 153. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 154. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 159. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 165. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 166. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 167. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 168. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 169. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Alpha 1 Antitrypsin Deficiency Treatment market report include:
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Biotest AG
  • Boehringer Ingelheim International GmbH
  • CSL Behring GmbH
  • GlaxoSmithKline plc
  • Grifols S.A.
  • Kamada Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages189
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.83 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.79 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Alpha 1 Antitrypsin Deficiency Treatment - Global Strategic Business Report - Product Image

Alpha 1 Antitrypsin Deficiency Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Alpha- Antitrypsin Deficiency - Pipeline Insight, 2025 - Product Image

Alpha- Antitrypsin Deficiency - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Alpha-1 Antitrypsin Deficiency Market - A Global and Regional Analysis: Focus on Treatment, Distribution Channel, and Regional Analysis - Analysis and Forecast, 2025-2035 - Product Image

Alpha-1 Antitrypsin Deficiency Market - A Global and Regional Analysis: Focus on Treatment, Distribution Channel, and Regional Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Alpha-1 Antitrypsin Deficiency- Pipeline Insight, 2025 - Product Image

Alpha-1 Antitrypsin Deficiency- Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type, Route of Administration, End User, and Region 2025-2033 - Product Image

Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type, Route of Administration, End User, and Region 2025-2033

  • Report
  • 123 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.